TOKYO, Sept. 24, 2019 /Kyodo JBN- AsiaNet/--
Nippon Express Co., Ltd. (TSE: 9062, the "Company"), acting through its subsidiary Nippon Express (South Asia & Oceania) Pte. Ltd. has agreed to make an investment in Future Supply Chain Solutions Limited ("FSC") ("Investment"). The Board of the Company, at its meeting held on September 20, 2019, approved the execution of a Share Subscription Agreement ("SSA") and Shareholder Agreement ("SHA") with FSC and a Share Purchase Agreement ("SPA") with some FSC shareholders. FSC, listed on BSE Limited and the National Stock Exchange of India Limited, is among India's leading logistics service providers and a part of the Future Group, India's largest retail group.
The investment is subject to customary closing conditions and regulatory approvals.
- Objective of the Investment
The Nippon Express Group aims to become a logistics company with a significant presence in the global markets as laid out in the "Nippon Express Group Business Plan 2023 - Dynamic Growth" beginning from financial year 2018. An important part of the group's core strategy is to focus on strengthening its India business to capitalize on the rapid growth expected in the Indian logistics market. The Indian logistics market is expected to have significant growth driven by key factors like 1) modernization of the road infrastructure network, 2) reorganization of traditional supply chain networks due to the implementation of GST (Goods and Service Tax) (*) and 3) consumption growth driven by a fast growing middle-income group.
Nippon Express first entered the Indian market in 2007 and currently focuses on international freight forwarding of cargo arriving in and departing from India. As a next step to further expand its India business, it is enhancing domestic logistics business in India to capture expanding domestic demand.
Headquartered in Mumbai, India, the Future Group is one of the largest business conglomerates engaged in modern retail trade with a pan-India footprint. The Future Group's rapid growth in retail business is supported by FSC's logistics capabilities. In a short span of time, FSC has established itself as one of the largest players in India, counting not only the Future Group as its anchor customer but also several fast-growing Indian and MNC customers.
The partnership with FSC will add complementary capabilities to Nippon Express and enable it to provide end-to-end logistics services to its customers resulting in the growth of its Indian logistics business. (*) GST (Goods and Services Tax): Indirect tax levied on the supply of goods and services.
For details, please visit:
https://kyodonewsprwire.jp/attach/201909191058-O1-4aKWNJ7y.pdf
- Outlook
The impact of the Investment on the consolidated performance of the Company for the fiscal year ending March 2020 will be minor.
SOURCE: Nippon Express Co., Ltd.
--BERNAMA
Tuesday, September 24, 2019
AM BEST AFFIRMS CREDIT RATINGS OF COSCO SHIPPING CAPTIVE INSURANCE CO., LTD.
HONG KONG, Sept 20 (Bernama-BUSINESS WIRE) -- AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of “a” of COSCO SHIPPING Captive Insurance Co., Ltd. (COSCO SHIPPING Captive) (China). The outlook of these Credit Ratings (ratings) is stable.
The ratings reflect COSCO SHIPPING Captive’s balance sheet strength, which AM Best categorizes as very strong, as well as its adequate operating performance, neutral business profile and appropriate enterprise risk management. The ratings also reflect the wide range of support the company receives from its parent, China COSCO SHIPPING Corporation Limited (COSCO SHIPPING), which AM Best perceives to benefit from strong government support.
COSCO SHIPPING Captive’s risk-adjusted capitalization remained at the strongest level in 2018, as measured by Best’s Capital Adequacy Ratio (BCAR), and is supported by very low underwriting leverage, a prudent reinsurance program and a conservative investment portfolio. Due to a large initial injection of RMB 2 billion (USD 283 million) in start-up capital, the captive insurer’s capital and surplus at year-end 2018 amounted to RMB 2.2 billion (USD 311 million), a level much higher than its regional peers. COSCO SHIPPING Captive has generated net operating profits each year since its inception in February 2017, which has contributed to organic growth in its capital and surplus. AM Best expects continued net profits from the company over the medium term, supported by its positive underwriting results and a stable stream of investment income.
COSCO SHIPPING Captive underwrites mainly marine-related business for the group and its affiliates, as well as other risks stemming from the group’s operations including cargo, liability, and commercial property. During fiscal year 2018, the captive achieved RMB 432 million (USD 61 million) in premium income, largely derived from its main line of business, marine hull, which is expected to remain as the company’s key revenue source over the medium term. As a strategically important member of COSCO SHIPPING, the captive receives various implicit and explicit support from its parent including business development, researching funding, managerial and capital support.
Offsetting rating factors include the captive’s small net premium base due to its high reinsurance dependency, as well as a high-severity, low-frequency product risk profile. As a result of the above, the captive is exposed to potential volatility in its underwriting results. However, this is mitigated partly through a robust reinsurance program with a high-quality reinsurer panel. As a start-up company, COSCO SHIPPING Captive faces execution risk in achieving its business plans, although this is mitigated through conservative assumptions and regular experience reviews.
Negative rating actions could occur if there is a reduced level of support from COSCO SHIPPING or a significant deterioration in COSCO SHIPPING's financial strength or credit profile. Negative rating actions also could occur if there is a material decline in the captive's risk-adjusted capitalization or if there is significant adverse deviation in the captive's operating performance from its business plan.
AM Best remains the leading rating agency of alternative risk transfer entities, with more than 200 such vehicles rated throughout the world. For current Best’s Credit Ratings and independent data on the captive and alternative risk transfer insurance market, please visit www.ambest.com/captive.
Ratings are communicated to rated entities prior to publication. Unless stated otherwise, the ratings were not amended subsequent to that communication.
This press release relates to Credit Ratings that have been published on AM Best’s website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best’s Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Understanding Best’s Credit Ratings. For information on the proper media use of Best’s Credit Ratings and AM Best press releases, please view Guide for Media - Proper Use of Best’s Credit Ratings and AM Best Rating Action Press Releases.
AM Best is a global credit rating agency and information provider with an exclusive focus on the insurance industry. Visit www.ambest.com for more information.
Copyright © 2019 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190919005746/en/
Contact
Yizhou Hong
Senior Financial Analyst
+852 2827 3426
yizhou.hong@ambest.com
Christie Lee
Senior Director, Analytics
+852 2827 3413
christie.lee@ambest.com
Christopher Sharkey
Manager, Public Relations
+1 908 439 2200, ext. 5159
christopher.sharkey@ambest.com
Jim Peavy
Director, Public Relations
+1 908 439 2200, ext. 5644
james.peavy@ambest.com
Source : AM Best
--BERNAMA
The ratings reflect COSCO SHIPPING Captive’s balance sheet strength, which AM Best categorizes as very strong, as well as its adequate operating performance, neutral business profile and appropriate enterprise risk management. The ratings also reflect the wide range of support the company receives from its parent, China COSCO SHIPPING Corporation Limited (COSCO SHIPPING), which AM Best perceives to benefit from strong government support.
COSCO SHIPPING Captive’s risk-adjusted capitalization remained at the strongest level in 2018, as measured by Best’s Capital Adequacy Ratio (BCAR), and is supported by very low underwriting leverage, a prudent reinsurance program and a conservative investment portfolio. Due to a large initial injection of RMB 2 billion (USD 283 million) in start-up capital, the captive insurer’s capital and surplus at year-end 2018 amounted to RMB 2.2 billion (USD 311 million), a level much higher than its regional peers. COSCO SHIPPING Captive has generated net operating profits each year since its inception in February 2017, which has contributed to organic growth in its capital and surplus. AM Best expects continued net profits from the company over the medium term, supported by its positive underwriting results and a stable stream of investment income.
COSCO SHIPPING Captive underwrites mainly marine-related business for the group and its affiliates, as well as other risks stemming from the group’s operations including cargo, liability, and commercial property. During fiscal year 2018, the captive achieved RMB 432 million (USD 61 million) in premium income, largely derived from its main line of business, marine hull, which is expected to remain as the company’s key revenue source over the medium term. As a strategically important member of COSCO SHIPPING, the captive receives various implicit and explicit support from its parent including business development, researching funding, managerial and capital support.
Offsetting rating factors include the captive’s small net premium base due to its high reinsurance dependency, as well as a high-severity, low-frequency product risk profile. As a result of the above, the captive is exposed to potential volatility in its underwriting results. However, this is mitigated partly through a robust reinsurance program with a high-quality reinsurer panel. As a start-up company, COSCO SHIPPING Captive faces execution risk in achieving its business plans, although this is mitigated through conservative assumptions and regular experience reviews.
Negative rating actions could occur if there is a reduced level of support from COSCO SHIPPING or a significant deterioration in COSCO SHIPPING's financial strength or credit profile. Negative rating actions also could occur if there is a material decline in the captive's risk-adjusted capitalization or if there is significant adverse deviation in the captive's operating performance from its business plan.
AM Best remains the leading rating agency of alternative risk transfer entities, with more than 200 such vehicles rated throughout the world. For current Best’s Credit Ratings and independent data on the captive and alternative risk transfer insurance market, please visit www.ambest.com/captive.
Ratings are communicated to rated entities prior to publication. Unless stated otherwise, the ratings were not amended subsequent to that communication.
This press release relates to Credit Ratings that have been published on AM Best’s website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best’s Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Understanding Best’s Credit Ratings. For information on the proper media use of Best’s Credit Ratings and AM Best press releases, please view Guide for Media - Proper Use of Best’s Credit Ratings and AM Best Rating Action Press Releases.
AM Best is a global credit rating agency and information provider with an exclusive focus on the insurance industry. Visit www.ambest.com for more information.
Copyright © 2019 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190919005746/en/
Contact
Yizhou Hong
Senior Financial Analyst
+852 2827 3426
yizhou.hong@ambest.com
Christie Lee
Senior Director, Analytics
+852 2827 3413
christie.lee@ambest.com
Christopher Sharkey
Manager, Public Relations
+1 908 439 2200, ext. 5159
christopher.sharkey@ambest.com
Jim Peavy
Director, Public Relations
+1 908 439 2200, ext. 5644
james.peavy@ambest.com
Source : AM Best
--BERNAMA
Monday, September 23, 2019
PRA HEALTH SCIENCES, SYMPHONY HEALTH LAUNCH METYS(TM) NATIONAL MARKET MEASUREMENT TOOL
The first of its kind, Metys(TM) delivers accurate, reliable data quickly through a single access point
RALEIGH, N.C., Sept 19 (Bernama-GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today the launch of Symphony Health’s new national market measurement tool – Metys™ (pronounced Met-IS), the only completely integrated, all-in-one market research solution available from a contract research organization (CRO).
The first platform of its kind, Metys delivers pharmaceutical market analytics and intelligence that is both timely and comprehensive. Now life sciences and other industries are better equipped to manage diverse portfolios with accuracy, reliability and agility.
Powered by IDV®, the company’s Integrated Dataverse, Metys intelligently integrates prescriber, payer, and patient data assets. Source of business, managed care and other key metrics are also included and provide a complete picture of market activity. Speed, ease of access, and insights are all hallmarks of Metys’ customizable dashboards and reporting. Metys™ is also the only national market measurement solution in the industry that includes linked diagnosis subgroups to projected prescriptions and writers.
“Because understanding, measuring and influencing treatment decisions is increasingly complex, PRA and Symphony Health have developed a solution that quickly and efficiently brings all of the data to clients’ fingertips within the Metys™ platform,” said Doug Fulling, President of Symphony Health. “This offering affirms our commitment to serving our clients at the highest level with tools that will move their business forward, while also reinforcing our culture of innovation and excellence.”
For more information about Metys visit www.symphonyhealth.com.
ABOUT PRA HEALTH SCIENCES
PRA (NASDAQ: PRAH) is a full-service global contract research organization, providing a broad range of product development and data solution services to pharmaceutical and biotechnology companies around the world. PRA’s integrated services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. PRA’s global operations span 90 countries across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and more than 16,000 employees. Since 2000, PRA has participated in more than 3,800 clinical trials. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 85 products. To learn more about PRA, please visit www.prahs.com.
INVESTOR INQUIRIES: InvestorRelations@prahs.com
MEDIA INQUIRIES:
Laurie Hurst, Director, Communications and Public Relations
HurstLaurie@prahs.com, +1.919.786.8435
ABOUT SYMPHONY HEALTH
A wholly-owned subsidiary of PRA Health Sciences, Symphony Health is a leading provider of high-value data, analytics, and technology solutions for biopharmaceutical manufacturers, healthcare providers, and payers. The company helps clients understand disease incidence, prevalence, progression, treatment, and influences along the patient and prescriber journeys by connecting and integrating a broad set of primary and secondary data, and providing health research, analytics, and consulting expertise. Symphony Health derived data improves health management decisions, and helps clients drive revenue growth while providing critical insights on how to effectively adapt to the changing healthcare ecosystem. For more information about Symphony Health, please visit www.symphonyhealth.com.
A video accompanying this release is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/60d0f7fa-d592-4014-a193-04bd810547f9
Source: PRA Health Sciences, Inc.
--BERNAMA
RALEIGH, N.C., Sept 19 (Bernama-GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today the launch of Symphony Health’s new national market measurement tool – Metys™ (pronounced Met-IS), the only completely integrated, all-in-one market research solution available from a contract research organization (CRO).
The first platform of its kind, Metys delivers pharmaceutical market analytics and intelligence that is both timely and comprehensive. Now life sciences and other industries are better equipped to manage diverse portfolios with accuracy, reliability and agility.
Powered by IDV®, the company’s Integrated Dataverse, Metys intelligently integrates prescriber, payer, and patient data assets. Source of business, managed care and other key metrics are also included and provide a complete picture of market activity. Speed, ease of access, and insights are all hallmarks of Metys’ customizable dashboards and reporting. Metys™ is also the only national market measurement solution in the industry that includes linked diagnosis subgroups to projected prescriptions and writers.
“Because understanding, measuring and influencing treatment decisions is increasingly complex, PRA and Symphony Health have developed a solution that quickly and efficiently brings all of the data to clients’ fingertips within the Metys™ platform,” said Doug Fulling, President of Symphony Health. “This offering affirms our commitment to serving our clients at the highest level with tools that will move their business forward, while also reinforcing our culture of innovation and excellence.”
For more information about Metys visit www.symphonyhealth.com.
ABOUT PRA HEALTH SCIENCES
PRA (NASDAQ: PRAH) is a full-service global contract research organization, providing a broad range of product development and data solution services to pharmaceutical and biotechnology companies around the world. PRA’s integrated services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. PRA’s global operations span 90 countries across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and more than 16,000 employees. Since 2000, PRA has participated in more than 3,800 clinical trials. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 85 products. To learn more about PRA, please visit www.prahs.com.
INVESTOR INQUIRIES: InvestorRelations@prahs.com
MEDIA INQUIRIES:
Laurie Hurst, Director, Communications and Public Relations
HurstLaurie@prahs.com, +1.919.786.8435
ABOUT SYMPHONY HEALTH
A wholly-owned subsidiary of PRA Health Sciences, Symphony Health is a leading provider of high-value data, analytics, and technology solutions for biopharmaceutical manufacturers, healthcare providers, and payers. The company helps clients understand disease incidence, prevalence, progression, treatment, and influences along the patient and prescriber journeys by connecting and integrating a broad set of primary and secondary data, and providing health research, analytics, and consulting expertise. Symphony Health derived data improves health management decisions, and helps clients drive revenue growth while providing critical insights on how to effectively adapt to the changing healthcare ecosystem. For more information about Symphony Health, please visit www.symphonyhealth.com.
A video accompanying this release is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/60d0f7fa-d592-4014-a193-04bd810547f9
Source: PRA Health Sciences, Inc.
--BERNAMA
Friday, September 20, 2019
CRYPTOCURRENCY MINING RIGS WITH ROI IN ONE MONTH RELEASED
WELLINGTON, New Zealand, Sept 18 (Bernama-GLOBE NEWSWIRE) -- Lyre Miner and Harp Miner, two crypto mining rigs launched recently by www.BitHarp.com, have opened up excellent investment opportunities for all types of investors. Unlike most other similar products available in the market, these two mining rigs have been specially designed and configured to let the beginners earn a decent return on their investment without having to delve deep into the technical aspects of mining. Most importantly, BitHarp promises 100% ROI in about a month, for both their products.
The hash rate powers delivered by Lyre Miner and Harp Miner are mentioned below.
Bitcoin: 335 TH/s (Lyre Miner) & 2000 TH/s (Harp Miner)
Litecoin: 55 GH/s (Lyre Miner) & 300 GH/s (Harp Miner)
Ethereum: 14 GH/s (Lyre Miner) & 75 GH/s (Harp Miner)
Dash: 9 TH/s (Lyre Miner) & 50 TH/s (Harp Miner)
The profitability of mining rigs depends significantly on their energy consumption and hash rate power. With energy consumptions of 600W and 2400W, Lyre Miner and Harp Miner can be used to mine Bitcoin, Litecoin, Ethereum, and Dash with extraordinarily high hash rate powers. Both these products are suitable for use in home, office, as well as data center.
Both the miners from BitHarp can be used at home because they operate without generating any great deal of noise or heat. With a touch screen operator interface, Lyre Miner is extremely easy for the users to operate or monitor. It can mine one coin at a time with the possibility to switch.
A main DLC (direct liquid cooling) mining rig, Harp Miner is capable of delivering ultimate safety and high hash rate power. The specific design of the product makes is tolerant to faults and capable of eliminating potential risks that are often associated with liquid cooling.
To find out more about Lyre Miner and Harp Miner, please visit https://www.bitharp.com/
About BitHarp: BitHarp is a New Zealand based cryptocurrency manufacturer of the most high-performance and flexible Mining rigs built with the goal of making mining easier and more profitable for investors.
Media contact
Alexa Zimine
alexa@bitharp.com
+64 9884 8279
Source: Bitharp Group Limited
--BERNAMA
The hash rate powers delivered by Lyre Miner and Harp Miner are mentioned below.
Bitcoin: 335 TH/s (Lyre Miner) & 2000 TH/s (Harp Miner)
Litecoin: 55 GH/s (Lyre Miner) & 300 GH/s (Harp Miner)
Ethereum: 14 GH/s (Lyre Miner) & 75 GH/s (Harp Miner)
Dash: 9 TH/s (Lyre Miner) & 50 TH/s (Harp Miner)
The profitability of mining rigs depends significantly on their energy consumption and hash rate power. With energy consumptions of 600W and 2400W, Lyre Miner and Harp Miner can be used to mine Bitcoin, Litecoin, Ethereum, and Dash with extraordinarily high hash rate powers. Both these products are suitable for use in home, office, as well as data center.
Both the miners from BitHarp can be used at home because they operate without generating any great deal of noise or heat. With a touch screen operator interface, Lyre Miner is extremely easy for the users to operate or monitor. It can mine one coin at a time with the possibility to switch.
A main DLC (direct liquid cooling) mining rig, Harp Miner is capable of delivering ultimate safety and high hash rate power. The specific design of the product makes is tolerant to faults and capable of eliminating potential risks that are often associated with liquid cooling.
To find out more about Lyre Miner and Harp Miner, please visit https://www.bitharp.com/
About BitHarp: BitHarp is a New Zealand based cryptocurrency manufacturer of the most high-performance and flexible Mining rigs built with the goal of making mining easier and more profitable for investors.
Media contact
Alexa Zimine
alexa@bitharp.com
+64 9884 8279
Source: Bitharp Group Limited
--BERNAMA
PRA HEALTH SCIENCES, SYMPHONY HEALTH LAUNCH METYS(TM) NATIONAL MARKET MEASUREMENT TOOL
The first of its kind, Metys(TM) delivers accurate, reliable data quickly through a single access point
RALEIGH, N.C., Sept 19 (Bernama-GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today the launch of Symphony Health’s new national market measurement tool – Metys™ (pronounced Met-IS), the only completely integrated, all-in-one market research solution available from a contract research organization (CRO).
The first platform of its kind, Metys delivers pharmaceutical market analytics and intelligence that is both timely and comprehensive. Now life sciences and other industries are better equipped to manage diverse portfolios with accuracy, reliability and agility.
Powered by IDV®, the company’s Integrated Dataverse, Metys intelligently integrates prescriber, payer, and patient data assets. Source of business, managed care and other key metrics are also included and provide a complete picture of market activity. Speed, ease of access, and insights are all hallmarks of Metys’ customizable dashboards and reporting. Metys™ is also the only national market measurement solution in the industry that includes linked diagnosis subgroups to projected prescriptions and writers.
“Because understanding, measuring and influencing treatment decisions is increasingly complex, PRA and Symphony Health have developed a solution that quickly and efficiently brings all of the data to clients’ fingertips within the Metys™ platform,” said Doug Fulling, President of Symphony Health. “This offering affirms our commitment to serving our clients at the highest level with tools that will move their business forward, while also reinforcing our culture of innovation and excellence.”
For more information about Metys visit www.symphonyhealth.com.
ABOUT PRA HEALTH SCIENCES
PRA (NASDAQ: PRAH) is a full-service global contract research organization, providing a broad range of product development and data solution services to pharmaceutical and biotechnology companies around the world. PRA’s integrated services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. PRA’s global operations span 90 countries across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and more than 16,000 employees. Since 2000, PRA has participated in more than 3,800 clinical trials. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 85 products. To learn more about PRA, please visit www.prahs.com.
INVESTOR INQUIRIES: InvestorRelations@prahs.com
MEDIA INQUIRIES:
Laurie Hurst, Director, Communications and Public Relations
HurstLaurie@prahs.com, +1.919.786.8435
ABOUT SYMPHONY HEALTH
A wholly-owned subsidiary of PRA Health Sciences, Symphony Health is a leading provider of high-value data, analytics, and technology solutions for biopharmaceutical manufacturers, healthcare providers, and payers. The company helps clients understand disease incidence, prevalence, progression, treatment, and influences along the patient and prescriber journeys by connecting and integrating a broad set of primary and secondary data, and providing health research, analytics, and consulting expertise. Symphony Health derived data improves health management decisions, and helps clients drive revenue growth while providing critical insights on how to effectively adapt to the changing healthcare ecosystem. For more information about Symphony Health, please visit www.symphonyhealth.com.
A video accompanying this release is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/60d0f7fa-d592-4014-a193-04bd810547f9
Source: PRA Health Sciences, Inc.
--BERNAMA
RALEIGH, N.C., Sept 19 (Bernama-GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today the launch of Symphony Health’s new national market measurement tool – Metys™ (pronounced Met-IS), the only completely integrated, all-in-one market research solution available from a contract research organization (CRO).
The first platform of its kind, Metys delivers pharmaceutical market analytics and intelligence that is both timely and comprehensive. Now life sciences and other industries are better equipped to manage diverse portfolios with accuracy, reliability and agility.
Powered by IDV®, the company’s Integrated Dataverse, Metys intelligently integrates prescriber, payer, and patient data assets. Source of business, managed care and other key metrics are also included and provide a complete picture of market activity. Speed, ease of access, and insights are all hallmarks of Metys’ customizable dashboards and reporting. Metys™ is also the only national market measurement solution in the industry that includes linked diagnosis subgroups to projected prescriptions and writers.
“Because understanding, measuring and influencing treatment decisions is increasingly complex, PRA and Symphony Health have developed a solution that quickly and efficiently brings all of the data to clients’ fingertips within the Metys™ platform,” said Doug Fulling, President of Symphony Health. “This offering affirms our commitment to serving our clients at the highest level with tools that will move their business forward, while also reinforcing our culture of innovation and excellence.”
For more information about Metys visit www.symphonyhealth.com.
ABOUT PRA HEALTH SCIENCES
PRA (NASDAQ: PRAH) is a full-service global contract research organization, providing a broad range of product development and data solution services to pharmaceutical and biotechnology companies around the world. PRA’s integrated services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. PRA’s global operations span 90 countries across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and more than 16,000 employees. Since 2000, PRA has participated in more than 3,800 clinical trials. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 85 products. To learn more about PRA, please visit www.prahs.com.
INVESTOR INQUIRIES: InvestorRelations@prahs.com
MEDIA INQUIRIES:
Laurie Hurst, Director, Communications and Public Relations
HurstLaurie@prahs.com, +1.919.786.8435
ABOUT SYMPHONY HEALTH
A wholly-owned subsidiary of PRA Health Sciences, Symphony Health is a leading provider of high-value data, analytics, and technology solutions for biopharmaceutical manufacturers, healthcare providers, and payers. The company helps clients understand disease incidence, prevalence, progression, treatment, and influences along the patient and prescriber journeys by connecting and integrating a broad set of primary and secondary data, and providing health research, analytics, and consulting expertise. Symphony Health derived data improves health management decisions, and helps clients drive revenue growth while providing critical insights on how to effectively adapt to the changing healthcare ecosystem. For more information about Symphony Health, please visit www.symphonyhealth.com.
A video accompanying this release is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/60d0f7fa-d592-4014-a193-04bd810547f9
Source: PRA Health Sciences, Inc.
--BERNAMA
A NEWLY PUBLISHED 451 RESEARCH STUDY: SIGNIFICANT PRODUCTIVITY GAINS FOR THE CONNECTED WORKFORCE BEING DRIVEN BY ADOPTION OF MOBILE FIRST, MESSAGING FIRST COMMUNICATIONS
A survey of IT Decision makers and employees shows that workplaces with inconsistent mobile messaging policy and tools not only limits productivity gains, but also opens the door to privacy, compliance and security risks
CHICAGO, Sept 18 (Bernama-GLOBE NEWSWIRE) -- A study released today by NetSfere, a secure enterprise messaging platform created by global mobility solutions provider Infinite Convergence, in conjunction with 451 Research, a leading information technology research and advisory company focusing on technology innovation and market disruption, found that flexibility in the workplace requires a mobile first, messaging first communications strategy to optimize productivity.
The study found that nearly half of both employees and IT decision makers surveyed believe they stand to gain six or more hours a week as a direct result of using their smartphones for business communication which is predominantly for messaging and collaboration. However, the right technology is needed, otherwise organizations set themselves up for fragmented collaboration and security risks.
“While IT decision makers and employees agree that productivity increases when smartphones are used for messaging and collaboration, consumer messaging apps are still primarily used,” said Raul Castanon-Martinez, Senior Analyst – Workforce Collaboration, 451 Research. “Whether they realize it or not, many organizations are playing with fire because they aren’t taking a comprehensive approach to business communication, mobile messaging and collaboration strategy.”
Other key findings from the report include:
CHICAGO, Sept 18 (Bernama-GLOBE NEWSWIRE) -- A study released today by NetSfere, a secure enterprise messaging platform created by global mobility solutions provider Infinite Convergence, in conjunction with 451 Research, a leading information technology research and advisory company focusing on technology innovation and market disruption, found that flexibility in the workplace requires a mobile first, messaging first communications strategy to optimize productivity.
The study found that nearly half of both employees and IT decision makers surveyed believe they stand to gain six or more hours a week as a direct result of using their smartphones for business communication which is predominantly for messaging and collaboration. However, the right technology is needed, otherwise organizations set themselves up for fragmented collaboration and security risks.
“While IT decision makers and employees agree that productivity increases when smartphones are used for messaging and collaboration, consumer messaging apps are still primarily used,” said Raul Castanon-Martinez, Senior Analyst – Workforce Collaboration, 451 Research. “Whether they realize it or not, many organizations are playing with fire because they aren’t taking a comprehensive approach to business communication, mobile messaging and collaboration strategy.”
Other key findings from the report include:
- Employees rely heavily on their smartphones and messaging for business communications; 64 percent of employees use their smartphones several times a day for work purposes
- Mobile messaging is the preferred way to communicate among Millennials, but this trend is extending to all age groups
- Mobile first is key for user adoption, with the majority of respondents showing a strong preference for mobile-first applications
- Security, compliance and productivity are key priorities for IT decision makers when it comes to business communications
- 80 percent of IT decision makers consider it ‘very important’ that their messaging tools be optimized for mobile-specific working
“It is clear that productivity gains delivered by mobile-first communication platforms, combined with instantaneous nature of messaging are huge, but they should be made available to employees without compromising the enterprise IT environment whether its security, compliance or reliability,” said Anurag Lal, CEO and President of Infinite Convergence Solutions. “If the enterprise fails to do this, employees will turn to consumer-grade apps that will limit productivity gains and put sensitive business information out in the public domain.”
IT decision makers are taking steps in the right direction, but more can be done
Security and productivity are key priorities for IT decision-makers when it comes to business communications. Nearly half of those surveyed noted that their organizations have a significant number of employees constantly traveling or working remotely, resulting in the need for secure messaging tools and digital workspaces. IT leaders are prioritizing scalability, security and productivity, while integrating consumer-driven innovations like video calling into corporate-issued collaboration platforms.
While the study found that IT decision makers understand what their organizations need for messaging and collaboration, it did identify several gaps in providing the right technologies for the modern work environment. Organizations still tend to address mobility as an added feature, rather than a mission-critical capability. Low adoption of corporate-issued messaging and collaboration platforms is proof, with 75 percent of employees stating that they use SMS for business purposes on a daily basis.
“The slow adoption of most corporate-issued collaboration platforms and the lack of support for secure mobile messaging should be a wakeup call to business leaders that they need to view mobile-first as their primary employee communication and collaboration channel,” said Lal. “While mobile communication improves productivity, consumer-grade apps result in fragmented collaboration, a limited role for IT and poses security risks to a business.”
For more information about the study, please visit the website.
About NetSfere
NetSfere is a secure enterprise messaging service from Infinite Convergence Solutions, Inc. NetSfere provides industry-leading security and message delivery capabilities, including global cloud-based service availability, device-to-device encryption, location-based features and administrative controls. The service leverages Infinite Convergence's experience in delivering mobility solutions to tier 1 mobile operators globally and technology that supports more than 400 million subscribers and over a trillion messages on an annual basis. NetSfere is also compliant with regulatory requirements, including the Health Insurance Portability and Accountability Act (HIPAA), Sarbanes-Oxley and others. For more information, visit www.netsfere.com.
About Infinite Convergence Solutions
Infinite Convergence Solutions, Inc. provides next-generation messaging and mobility solutions to carriers and enterprises globally, including an Enterprise Messaging Services suite, secure messaging through its standalone service NetSfere (www.netsfere.com) and SMS, MMS and RCS solutions. The company's technology supports more than 400 million subscribers and over a trillion messages on an annual basis. Infinite Convergence Solutions has offices in the United States, Germany, India and Singapore.
About 451 Research
451 Research is a leading information technology research and advisory company focusing on technology innovation and market disruption. More than 100 analysts and consultants provide essential insight to more than 1,000 client organizations globally through a combination of syndicated research and data, advisory and go-to-market services, and live events. Founded in 2000 and headquartered in New York, 451 Research is a division of The 451 Group.
Contact
Colette McLaughlin
Uproar PR for Infinite Convergence
cmclaughlin@uproarpr.com
312-878-4575 x240
Source: Infinite Convergence Solutions
--BERNAMA
IT decision makers are taking steps in the right direction, but more can be done
Security and productivity are key priorities for IT decision-makers when it comes to business communications. Nearly half of those surveyed noted that their organizations have a significant number of employees constantly traveling or working remotely, resulting in the need for secure messaging tools and digital workspaces. IT leaders are prioritizing scalability, security and productivity, while integrating consumer-driven innovations like video calling into corporate-issued collaboration platforms.
While the study found that IT decision makers understand what their organizations need for messaging and collaboration, it did identify several gaps in providing the right technologies for the modern work environment. Organizations still tend to address mobility as an added feature, rather than a mission-critical capability. Low adoption of corporate-issued messaging and collaboration platforms is proof, with 75 percent of employees stating that they use SMS for business purposes on a daily basis.
“The slow adoption of most corporate-issued collaboration platforms and the lack of support for secure mobile messaging should be a wakeup call to business leaders that they need to view mobile-first as their primary employee communication and collaboration channel,” said Lal. “While mobile communication improves productivity, consumer-grade apps result in fragmented collaboration, a limited role for IT and poses security risks to a business.”
For more information about the study, please visit the website.
About NetSfere
NetSfere is a secure enterprise messaging service from Infinite Convergence Solutions, Inc. NetSfere provides industry-leading security and message delivery capabilities, including global cloud-based service availability, device-to-device encryption, location-based features and administrative controls. The service leverages Infinite Convergence's experience in delivering mobility solutions to tier 1 mobile operators globally and technology that supports more than 400 million subscribers and over a trillion messages on an annual basis. NetSfere is also compliant with regulatory requirements, including the Health Insurance Portability and Accountability Act (HIPAA), Sarbanes-Oxley and others. For more information, visit www.netsfere.com.
About Infinite Convergence Solutions
Infinite Convergence Solutions, Inc. provides next-generation messaging and mobility solutions to carriers and enterprises globally, including an Enterprise Messaging Services suite, secure messaging through its standalone service NetSfere (www.netsfere.com) and SMS, MMS and RCS solutions. The company's technology supports more than 400 million subscribers and over a trillion messages on an annual basis. Infinite Convergence Solutions has offices in the United States, Germany, India and Singapore.
About 451 Research
451 Research is a leading information technology research and advisory company focusing on technology innovation and market disruption. More than 100 analysts and consultants provide essential insight to more than 1,000 client organizations globally through a combination of syndicated research and data, advisory and go-to-market services, and live events. Founded in 2000 and headquartered in New York, 451 Research is a division of The 451 Group.
Contact
Colette McLaughlin
Uproar PR for Infinite Convergence
cmclaughlin@uproarpr.com
312-878-4575 x240
Source: Infinite Convergence Solutions
--BERNAMA
Subscribe to:
Posts (Atom)